FEMALE INFERTILITY: MODERN DIAGNOSTIC APPROACHES, ASSISTED REPRODUCTIVE TECHNOLOGIES, AND INDIVIDUALIZED TREATMENT OPTIONS
Keywords:
female infertility, reproductive health, ovulatory dysfunction, ovarian reserve, tubal infertility, endometriosis, polycystic ovary syndrome, hormonal assessment, pelvic ultrasonography, hysterosalpingography, assisted reproductive technology, in vitro fertilization, intracytoplasmic sperm injection, individualized treatment, reproductive counseling.Abstract
Female infertility remains a significant reproductive health challenge worldwide, affecting individuals, families, and healthcare systems. Its clinical complexity arises from the interaction of endocrine, anatomical, genetic, age-related, and environmental factors that may independently or collectively impair reproductive function. Contemporary reproductive medicine increasingly emphasizes early diagnosis, comprehensive evaluation of both partners, and individualized treatment planning based on the underlying cause of infertility. This article examines modern diagnostic approaches to female infertility, the clinical applications of assisted reproductive technologies, and the principles of personalized reproductive care. A narrative review of international clinical guidelines, peer-reviewed scientific publications, and selected literature relevant to reproductive healthcare in Uzbekistan was undertaken. The analysis focuses on ovulatory dysfunction, diminished ovarian reserve, tubal and peritoneal disorders, endometriosis, uterine abnormalities, and unexplained infertility. Particular attention is given to the diagnostic value and limitations of hormonal investigations, transvaginal ultrasonography, ovarian reserve markers, and tubal patency assessment. The reviewed evidence indicates that a structured diagnostic pathway can facilitate the identification of clinically significant reproductive abnormalities while reducing unnecessary investigations and delays in treatment. Anti-Müllerian hormone measurement and antral follicle count are useful for estimating ovarian response to stimulation, but neither should be interpreted independently as a definitive predictor of natural conception or live birth. Treatment selection should reflect female age, infertility duration, ovarian reserve, tubal status, semen parameters, previous treatment outcomes, associated medical conditions, and patient preferences. Ovulation induction remains an important option for selected patients with anovulatory infertility, whereas intrauterine insemination, in vitro fertilization, and intracytoplasmic sperm injection may be appropriate for specific clinical indications. Advances in ovarian stimulation, embryo culture, cryopreservation, and embryo-transfer strategies have expanded reproductive options, although treatment safety and realistic counseling remain essential. The review also highlights the importance of preconception care, psychological support, equitable access to fertility services, and transparent reporting of reproductive outcomes. In conclusion, effective infertility management requires the integration of evidence-based diagnostics, individualized therapeutic decisions, and multidisciplinary care. Further prospective research in Uzbekistan is needed to evaluate diagnostic delays, treatment accessibility, cumulative live-birth outcomes, and the economic and psychosocial consequences of infertility.
References
1. World Health Organization. Guideline for the Prevention, Diagnosis and Treatment of Infertility. Geneva: World Health Organization; 2025. 262 p. ISBN: 978-92-4-011577-4.
2. American Society for Reproductive Medicine, Practice Committee. Fertility Evaluation of Infertile Women: A Committee Opinion. Fertility and Sterility. 2021;116(5):1255–1265. Publisher: Elsevier.
3. Teede H.J., Tay C.T., Laven J.J.E., et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023;120(4):767–793. Publisher: Elsevier. DOI: 10.1016/j.fertnstert.2023.07.025.
4. Legro R.S., Brzyski R.G., Diamond M.P., et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. The New England Journal of Medicine. 2014;371:119–129. Publisher: Massachusetts Medical Society. DOI: 10.1056/NEJMoa1313517.
5. Practice Committee of the American Society for Reproductive Medicine. Testing and Interpreting Measures of Ovarian Reserve: A Committee Opinion. Fertility and Sterility. 2020;114(6):1151–1157. Publisher: Elsevier.
6. Republic of Uzbekistan. On the Protection of Reproductive Health of Citizens. Tashkent: Government of the Republic of Uzbekistan. The law number, adoption date, and official publication details should be verified against the current official legal text before submission.
7. Zokirov F.I., Pardaeva O.G. Opportunities of Different Approaches in Management of Secondary Infertility in Women. Journal of Reproductive Health and Uro-Nephrology Research. 2024;5(3). Publisher: Samarkand State Medical University. The complete page range should be confirmed from the original publication.
8. Khudoyarova D.R., Shopulotova Z.A. Infertility: Causes and Ways to Overcome. Eurasian Journal of Medical and Natural Sciences. 2024. Publisher: Innovative Academy Research Support Center. DOI: 10.5281/zenodo.13849364. The volume, issue, and page range should be verified against the published version.
9. Zegers-Hochschild F., Adamson G.D., Dyer S., et al. The International Glossary on Infertility and Fertility Care, 2017. Fertility and Sterility. 2017;108(3):393–406. Publisher: Elsevier. DOI: 10.1016/j.fertnstert.2017.06.005.
10. Homidova S. New Methods for Detecting and Treatment of Infertility of Tube-Peritoneal Genesis. Eurasian Journal of Medical and Natural Sciences. 2022;2(6):351–354. Publisher: Innovative Academy Research Support Center.